Research ArticleNuclear Oncology
Whole-Body FDG-PET Imaging for Staging of Hodgkin's Disease and Lymphoma
Carl K. Hoh, John Glaspy, Peter Rosen, Magnus Dahlbom, Shay J. Lee, Lori Kunkel, Randall A. Hawkin, Jamshid Maddahi and Michael E. Phelps
Journal of Nuclear Medicine March 1997, 38 (3) 343-348;
Carl K. Hoh
John Glaspy
Peter Rosen
Magnus Dahlbom
Shay J. Lee
Lori Kunkel
Randall A. Hawkin
Jamshid Maddahi
This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Whole-Body FDG-PET Imaging for Staging of Hodgkin's Disease and Lymphoma
Carl K. Hoh, John Glaspy, Peter Rosen, Magnus Dahlbom, Shay J. Lee, Lori Kunkel, Randall A. Hawkin, Jamshid Maddahi, Michael E. Phelps
Journal of Nuclear Medicine Mar 1997, 38 (3) 343-348;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
- Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
- Role of Positron Emission Tomography in Lymphoma
- Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
- Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation
- Overview of clinical PET
- PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease
- Challenging Cases and Diagnostic Dilemmas: Case 2. Pitfalls of Positron Emission Tomography for Assessing Residual Mediastinal Mass After Chemotherapy for Hodgkin's Disease
- Clinical Applications of 18F-FDG in Oncology
- Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
- Whole body applications of positron emission tomography in oncology
- Effect of Whole-Body 18F-FDG PET Imaging on Clinical Staging and Management of Patients with Malignant Lymphoma
- Impact of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography on Patient Management: First Year's Experience in a Clinical Center
- A Tabulated Summary of the FDG PET Literature
- FDG PET Imaging in Patients with Lymphoma: A Clinical Perspective
- Whole-Body Hybrid PET with 18F-FDG in the Staging of Non-Hodgkin's Lymphoma
- Somatostatin Receptor Scintigraphy in the Initial Staging of Low-Grade Non-Hodgkin's Lymphomas
- Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin's Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
- Nodal Staging of Lymphoma with Whole-Body PET: Comparison of [11C]Methionine and FDG
- Detection of Lymphoma in Bone Marrow by Whole-Body Positron Emission Tomography